Advances in the mechanism and therapeutic potential of Erianin-induced apoptosis in breast cancer cells
10.3969/j.issn.1006-5725.2025.14.002
- VernacularTitle:毛兰素诱导乳腺癌细胞凋亡的机制及治疗潜力的研究进展
- Author:
Jingshuo LI
1
;
Shoushi LIU
;
Hongwei GUO
Author Information
1. 广西医科大学第一临床医学院(广西南宁 530021);长寿与老年相关疾病教育部重点实验室,广西医科大学转化医学研究中心(广西南宁 530021)
- Publication Type:Journal Article
- Keywords:
Erianin;
triple-negative breast cancer;
apoptosis;
mitochondrial dysfunction;
caspase activation
- From:
The Journal of Practical Medicine
2025;41(14):2132-2137
- CountryChina
- Language:Chinese
-
Abstract:
This review systematically elucidates recent advances in the therapeutic application of Erianin,a natural compound derived from Dendrobium,a traditional Chinese medicine,in the treatment of breast cancer,with particular emphasis on triple-negative breast cancer(TNBC).TNBC is characterized by the absence of estrogen receptor(ER),progesterone receptor(PR),and human epidermal growth factor receptor 2(HER2)expression,which presents significant clinical challenges due to limited therapeutic targets and continued reliance on conventional chemotherapy.Erianin exhibits notable anticancer potential through the induction of apoptosis in breast cancer cells.Its primary mechanisms involve sensitizing cancer cells to apoptotic signals via activation of both intrinsic and extrinsic apoptotic pathways,particularly through mitochondrial dysfunction-mediated cytochrome c release and subsequent activation of caspase-dependent pathways.At the molecular level,Erianin effectively modulates key oncogenic signaling pathways,including PI3K/Akt,MAPK,and NFATc1 cascades,thereby sup-pressing cell proliferation and migration while promoting apoptosis.However,current research priorities center on investigating its synergistic effects with chemotherapeutic agents and assessing its radiosensitization potential to further enhance its clinical utility.Notably,Erianin demonstrates unique advantages in overcoming drug resistance in TNBC by modulating apoptotic regulatory networks,particularly through regulation of the Bax/Bcl-2 protein ratio,positioning it as a promising multi-target therapeutic candidate.Although existing evidence largely stems from in vitro and animal studies,future research should prioritize human clinical trials to validate its efficacy and safety,along-side pharmaceutical optimization strategies such as the development of nanodelivery systems and exploration of structural derivatives.This review systematically clarifies the core mechanism and therapeutic potential of pilanin-induced apoptosis,and provides theoretical basis for developing innovative therapeutic regimens for TNBC.
